Page 23 - Volume13_Issue3
P. 23
VOLUME 13 | ISSUE 3
HOPA has earned greater recognition
from external groups and an increasing
number of invitations to “sit at the table”
on the national practice and policy stage.
Also in June, HOPA was among a and opportunity for improvement with the Biosimilar Summit, the Drinker-Biddle
select group of 350 invited to attend Vice product label of oncology drugs. Client Advocacy Summit, and ISMP
President Joe Biden’s Cancer Moonshot collaboration, among others. These efforts
Summit in Washington, DC. HOPA’s health Finally, one very important table that are layered on top of our already excellent
policy advisor, Jeremy Scott from District HOPA has sought a chair at has been continuing education programs, three live
Policy Group, and I went on HOPA’s granted. Since the spring of 2014, at the conferences, our inaugural offering of the
behalf and attended four separate small suggestion of then-secretary Daisy Yang, BCOP Recertification Program, advocacy
group sessions with White House staff to the president and executive director of on our health policy agenda, continued
recommend ways in which the nation could HOPA have attended the quarterly meet- work refining a new committee structure,
“cure cancer once and for all” and specif- ings of the Joint Commission of Pharmacy and research agenda. As a member since
ically explain how oncology pharmacists Practitioners (JCPP) as guests with the 2005, it is so impressive to see our organi-
support patients with cancer as a chronic intention of requesting membership in the zation grow from a residency conference to
disease. In addition to offering ideas to the JCPP. When we first began, JCPP was in a premier resource for oncology pharmacy
Vice President, we networked with many the process of re-evaluating its member- education, and now layering on a more
other nonprofit and for-profit companies ship structure and later had some hesitan- sophisticated advocacy agenda. HOPA has
and have been contacted by some for cy about the role of specialty organizations earned greater recognition from external
additional collaborations in follow-up to within the JCPP. On August 2, Suzanne groups and an increasing number of invi-
the Moonshot Summit. In fact, HOPA Simons and I presented our case to the tations to “sit at the table” on the national
was invited to participate in a conference JCPP CEOs and the full JCPP audience; at practice and policy stage. It is well-de-
co-chaired by ASCO and Discern Health on the conclusion of that meeting, we received served recognition that demonstrates the
defining value and value-based metrics in a verbal “you’re in” from the JCPP chair. evolving maturity of our organization and
cancer care. We expect to hear more details formally particularly the expertise of our members
after the next meeting of the JCPP on and dedication to cancer patients. Kudos
Several HOPA members and I presented November 29, as the group continues to to you!
at the U.S. Food and Drug Administration define its new membership structure.
(FDA) on August 22 at the invitation of
the Office of Hematology and Oncology There are several other ongoing col-
Products. The FDA is interested in the laborations that we are involved in or will
perspectives of oncology pharmacists in have future representation in—the ASHP/
different practice settings on the utility HOPA pharmacy technician standard, the
National Comprehensive Cancer Network
23
